Key result
Valve replacement in young adults resulted in 15-year survival rates of 80.1% after AVR and 71.5% after MVR, with equivalent late survival between bioprosthetic and mechanical valves.
Why the study?
Does bioprosthetic valve replacement improve survival, functional status, and quality of life compared to mechanical valve replacement in young adults (age 18-50) undergoing AVR or MVR?
Cohort (n=500)
Does bioprosthetic valve replacement improve survival, functional status, and quality of life compared to mechanical valve replacement in young adults (age 18-50) undergoing AVR or MVR?
In young adults undergoing valve replacement, bioprostheses offer equivalent long-term survival to mechanical valves but are associated with better physical capacity and lower disability, particularly in the aortic position.
Answers are grounded in this paper and cite their sources.
Equivalent survival supports individualized bioprosthetic choice in young adults for potential functional gains; leaves open causal confirmation by randomized trials.
OBJECTIVES: To examine the multiple impacts of valve replacement on the lives of young adults. METHODS: Patients (N=500) between age 18 and 50 who had aortic valve replacement (AVR) and/or mitral valve replacement (MVR) with contemporary prostheses were followed annually. Events, functional status, and quality of life were examined with regression models. RESULTS: Median follow-up was 7.1+/-5.3 years (maximum 26.7 years). Five, 10, and 15-year survival was 92.7+/-1.7, 88.3+/-2.4 and 80.1+/-4.7% after AVR, and 93.1+/-2.3, 79.5+/-4.3 and 71.5+/-5.4% after MVR, respectively. Survival decreased with concomitant coronary disease (hazard ratio (HR): 4.5) and preoperative LV grade (HR: 2.0/grade increase) in AVR patients, and with atrial fibrillation (HR: 5.5), coronary disease (HR: 5.7), preoperative left atrial diameter (HR: 3.0/cm increase) and NYHA class (HR: 2.1/class increase) in MVR patients. Despite reoperation, late survival was equivalent between bioprostheses and mechanical valves in both implant positions. The ten-year cumulative incidence of embolic stroke was 6.3+/-2.4% for mechanical AVR patients, 6.4+/-2.9% for bioprosthetic AVR patients, 12.7+/-3.9% for mechanical MVR patients, and 3.1+/-3.1% for bioprosthetic MVR patients. Atrial fibrillation (HR: 2.8) and smoking (HR: 4.0) were risk factors for stroke in MVR patients. In AVR patients, SF-12 physical scores, freedom from recurrent heart failure, and freedom from disability were significantly higher in bioprosthetic than mechanical valve patients. Career or income limitations were more often subjectively linked to a mechanical prosthesis in both implant positions. CONCLUSIONS: Late outcomes of modern prosthetic valves in young adults remain suboptimal. Bioprostheses deserve consideration in the aortic position, as mechanical valves are associated with lower physical capacity, a higher prevalence of disability, and poorer disease perception. Early surgical referral and atrial fibrillation surgery may improve survival after MVR.
No takes yet. Share an insight, caveat, or question.
Ruel et al. (2004) conducted a cohort in Aortic and/or mitral valve disease requiring replacement (n=500). Valve replacement with contemporary prostheses vs. Mechanical vs bioprosthetic valves was evaluated on Survival, events, functional status, and quality of life. Valve replacement in young adults resulted in 15-year survival rates of 80.1% after AVR and 71.5% after MVR, with equivalent late survival between bioprosthetic and mechanical valves.
Synapse has enriched 10 related papers. Consider them for comparative context: